Navigation Links
DuraSoft Knee Sleeve and Knee Wrap

ProductsDuraSoft Knee Sleeve and Knee Wrap
Company DJO Incorporated
Item DuraSoft Knee Sleeve and Knee Wrap
Features 
  • Removable DuraSoft inserts allow for continuous cryotherapy
  • The malleable packs and elastic straps on the wraps provide optimal compression
  • The knee sleeve is designed to load the packs into anterior pockets for easy exchange of ice packs
    • Description Provides continuous cold therapy to the knee area for acute, chronic, or post-surgical applications. Cryotherapy can reduce pain, swelling and facilitate faster rehabilitation.
    Info DJO Incorporated
    Customer Service: (888) 624-5450
    Web site: http://www.djortho.com/

    Related medicine products :

    1. DuraSoft Shoulder Wrap and Back Wrap
    2. Silicone Sleeve (70 Style)
    3. Silicone Sleeve (270 Style)
    4. VanRens Sleeve Spreading Forceps
    5. Lambert Sleeve Spreader
    6. Watzke Sleeve Spreading Forceps
    7. Ti/HA Peg & Sleeve System
    8. Ligature Sleeve
    9. Universal Adaptor Sleeve
    10. Universal I/A handpiece - Stainless steel (Straight Silicone Sleeve Tip, Size: 19g Aspiration Cannula)
    11. Universal I/A handpiece - Titanium (Straight Silicone Sleeve Tip, Size: 19g Aspiration Cannula)
    Set consist of two 27 gauge, stainless steel probes with Crawford Olive tips. Probes are 11.5 cm (4.5 inches) long with 30.5 cm (12 inches) of flexible tubing (O.D. - 0.60 mm, I.D. - 0.30 mm) attache
    Sharp tip with cutting edge bent to 45 degrees. Fits 19 gauge or 20 gauge instrument port. 21 gauge x 25 mm. 10 per box.
    19 gauge x 8 mm with 15 cm high pressure extension tube preattached to a 10C ring control syringe. 3 per box.
    Sharp tip with cutting edge bent to 50 degrees fits 19 gauge or 20 gauge instrument port, 20 gauge instrument port, 20 gauge x 25 mm tapering to 25 gauge x 4.76 mm. 10 per box.
    Medicine Products:
    (Date:12/3/2008)...A patient who was surgically implanted,with Medtr...bel use promoted,by Medtronic, suffocated due to ...es A. Dunlap Jr. & Associates LLC and Page Per... with another national law firm. , The Comp...improperly,promoted its Infuse(R) Bone Graft prod...
    (Date:12/3/2008)... for screening yet, experts say, , , ...east imaging techniques will help doctors diagnose...ll replace standard mammography for the detection ...ic gamma imaging (BSGI) and positron emission mamm...o detect cancer cells. The tracer used in BSGI is ...
    (Date:12/3/2008)...up health benchmark data providing information by ...f industries , , SAN FRANCISCO, Dec. 3 /PRN... the need for and effectiveness of their health an... Integrated Benefits Institute (IBI) announced tod... Not only does IBI,s benchmarking offer the abilit...
    (Date:12/3/2008)...have proven definitively that blood stem cells are... by endothelial cells, the cells that line the ins...ation in the embryo where blood stem cells origina...ich they spring was less understood. The UCLA find...urnal Cell Stem Cell , puts to rest a long-standi...
    Breaking Medicine News(10 mins):Health News:Medtronic, Inc. and Medtronic Sofamor Danek, USA, Inc. Sued for Product Liability and Promoting the Off-Label Use of Infuse(R) Bone Graft Product, According to Page Perry, LLC 2Health News:Latest Breast Imaging Techniques Offer New Views 2Health News:Latest Breast Imaging Techniques Offer New Views 3Health News:Integrated Benefits Institute Announces Availability of 2007 IBI Benchmarking Data for Employers to Evaluate Effectiveness of their Health and Productivity Programs 2Health News:UCLA scientists prove endothelial cells give rise to blood stem cells 2Health News:UCLA scientists prove endothelial cells give rise to blood stem cells 3
    ...who feel less than that, after a lumpectomy for br...pany Cytori, claim that stem cells found in the ub...truct breasts. If this is so, it would be killing ...ly and a bigger bust size. Christened Celution, th...
    ...iterature found that delays could be generally att...inical presentation and stage of disease, as well ...t further research should focus on understanding t...morbidity and mortality in children with cancer. ...
    ...at the Keck School of Medicine of the University o...seven genetic risk factors previously identified ...te cancer also increases the probability of develo...evious prostate cancer study, which was also condu...
    ...get of supplying 150,000 HIV sufferers with free a...of the national AIDS commission (NAC) said on Mond...we hope to hit 150,000 by the end of December when...scale-up of the drugs" from September, NAC chief B...
    Other Medicine News:Health News:Stem Cells In Belly Fat To Enhance Or Reconstruct Breasts 2Health News:Delay in Cancer Diagnosis for Children 2Health News:Delay in Cancer Diagnosis for Children 3Health News:Genetic Risk Factor for Prostate Cancer 2
    (Date:12/3/2008)...LE, Pa., Dec. 3 Wyeth Ph..., announced today that it has submitted a,marketi... Medicines Agency,(EMEA) for approval to market i...te vaccine (PCV13) for infants and young children....on of pneumococcal disease (PD) caused by the 13,...
    (Date:12/3/2008)..., Calif., Dec. 3 Bionovo... FDA has reviewed the company,s,manufacturing and...ded,guidance on how Bionovo can move forward with...) for menopausal hot flashes. , "We have co...e moving to,address the Agency,s recommendations ...
    (Date:12/2/2008)...ec. 3 Breast-specific g... of cancers not found on mammograms or by,clinica...e annual meeting of,the Radiological Society of N...he most difficult to detect breast cancer-invasive...rem, M.D., professor of,radiology and director of...
    (Date:12/2/2008)...Calif., Dec. 2 TorreyPines Therape...tive results from a 26 patient Phase II trial eval...rostomia, or dry mouth, in patients with Sjogren,s...tatistically significant increase in salivary flow...: 10 mg, 15 mg, and 20 mg. These doses were safe a...
    Breaking Medicine Technology:Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 2Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 3Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 4Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 5Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings 2Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings 3Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings 4New Breast Imaging Technology Targets Hard-to-Detect Cancers 2New Breast Imaging Technology Targets Hard-to-Detect Cancers 3TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 2TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 3TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 4TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 5SEAL Indiana Reports More Than Half of Indianapolis Area School Kids Treated by Program Have Moderate or Severe Dental Decay 27390 1SEAL Indiana Reports More Than Half of Indianapolis Area School Kids Treated by Program Have Moderate or Severe Dental Decay 27390 2SEIU Members Stepping up Their Efforts for Obama Biden Ticket 27387 1SEIU Members Stepping up Their Efforts for Obama Biden Ticket 27387 2deCODE Conducting Strategic Review to Sharpen the Focus of its Long term Business 27384 1deCODE Conducting Strategic Review to Sharpen the Focus of its Long term Business 27384 2deCODE Conducting Strategic Review to Sharpen the Focus of its Long term Business 27384 3deCODE Conducting Strategic Review to Sharpen the Focus of its Long term Business 27384 4Fourth Hand Transplant Recipient Heads Home to California 27382 1Fourth Hand Transplant Recipient Heads Home to California 27382 2
    ...am versus placebo: - 25,/ - 13 mm Hg (systolic / d...on vaccine dose and induced,antiangiotensin II ant...t the Seventeenth European,Meeting on Hypertension...d and MILAN, Italy, June 17, 2007 -,Cytos Biotechn...ata,on its hypertension vaccine CYT006-AngQb at th...
    ...Intramuscular Formulation,of Peramivir Supports Fu... BIRMINGHAM, Ala., June 18, 2007 /PRNewswire-First...results from two Phase I,clinical studies of an in... Options for the Control of Influenza Conference i...al influenza,conference is held only once every fo...
    Other Medicine Technology:Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 2Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 3Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 4Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 5Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 6Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 7Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 8Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 9BioCryst Presents Phase I Peramivir Data at the Options for the,Control of Influenza Conference 2BioCryst Presents Phase I Peramivir Data at the Options for the,Control of Influenza Conference 3BioCryst Presents Phase I Peramivir Data at the Options for the,Control of Influenza Conference 4BioCryst Presents Phase I Peramivir Data at the Options for the,Control of Influenza Conference 5BioCryst Presents Phase I Peramivir Data at the Options for the,Control of Influenza Conference 6